Dr. Tagawa is the Richard A. Stratton Associate Professor in Hematology and Oncology, an Associate Professor of Clinical Medicine & Urology, at Weill Cornell Medicine, and an Associate Attending Physician at New York Presbyterian - WCMC. His research has involved clinical and translational investigations in genitourinary tumors and thrombosis in malignancy. As the Medical Director of the Genitourinary Oncology Research Program, he leads clinical trials in the areas of prostate, kidney and bladder cancers, as well as the prevention and treatment of thrombosis with cancer. He is particularly focused on drug development and theranostics in prostate cancer. Dr. Tagawa serves as Associate Director of Clinical Research for the Division of Hematology and Medical Oncology and Chair of the Clinical Study Evaluation (scientific review) Committee for cancer. He is the WCMC principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a member of the Genitourinary Committee.The event is intended for institutional investors and sell-side analysts. If you would like to attend in person, please contact Mac MacDonald at 212-915-2567 or via e-mail at Mac@LifeSciAdvisors.com to reserve a place. A live webcast of the event, with slides, will be available at http://lifesci.rampard.com/20161201/reg.jsp and within the Investors section of the Company's website at http://ir.traconpharma.com. About TRC105TRC105 (carotuximab) is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in multiple Phase 2 clinical trials sponsored by TRACON or the National Cancer Institute for the treatment of solid tumor types in combination with VEGF inhibitors. The ophthalmic formulation of TRC105, DE-122, is currently in a Phase 1/2 trial for patients with wet AMD. TRC205, a second generation antibody to endoglin, is undergoing preclinical testing in models of fibrosis. About TRC253TRC253 is a novel, orally bioavailable small molecule that is a potent, high affinity antagonist of wild type and mutated androgen receptors, including mutations associated with resistance to Xtandi® (enzalutamide). TRC253 was discovered and initially developed by Janssen and is now under development by TRACON for the treatment of men with prostate cancer. IND-enabling studies have been completed. About TRACONTRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company's clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. The Company is also developing two programs in-licensed from Janssen Pharmaceutica N.V. - TRC253, a small molecule inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that may display drug resistance, which is intended for the treatment of men with prostate cancer, and TRC694, a small molecule inhibitor of NF-kB inducing kinase (NIK), which is intended for the treatment of patients with hematologic malignancies, including myeloma.
Company Contact:Casey LoganChief Business Officer(858) 550-0780 ext. email@example.comInvestor Contact:Andrew McDonaldLifeSci Advisors LLC646-597-6987Andrew@lifesciadvisors.com